Canada markets open in 6 hours 41 minutes

  • S&P/TSX

    19,800.61
    +20.64 (+0.10%)
     

  • S&P 500

    4,337.44
    +17.38 (+0.40%)
     

  • DOW

    34,006.88
    +43.04 (+0.13%)
     

  • CAD/USD

    0.7414
    -0.0020 (-0.27%)
     

  • CRUDE OIL

    88.71
    -0.97 (-1.08%)
     

  • Bitcoin CAD

    35,452.21
    +168.64 (+0.48%)
     

  • CMC Crypto 200

    562.41
    +2.90 (+0.52%)
     

  • GOLD FUTURES

    1,930.60
    -6.00 (-0.31%)
     

  • RUSSELL 2000

    1,784.24
    +7.74 (+0.44%)
     

  • 10-Yr Bond

    4.5420
    0.0000 (0.00%)
     

  • NASDAQ futures

    14,835.50
    -99.75 (-0.67%)
     

  • VOLATILITY

    16.90
    -0.30 (-1.74%)
     

  • FTSE

    7,623.99
    -59.92 (-0.78%)
     

  • NIKKEI 225

    32,315.05
    -363.57 (-1.11%)
     

  • CAD/EUR

    0.7005
    -0.0010 (-0.14%)
     

Vir Biotechnology to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference

Vir Biotechnology, Inc.
·1 min read
Vir Biotechnology, Inc.
Vir Biotechnology, Inc.

SAN FRANCISCO, June 05, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate in a fireside chat at the 44th Annual Goldman Sachs Global Healthcare Conference on Monday, June 12, at 10:40 a.m. PT / 1:40 p.m. ET.

A live webcast of the presentation can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there for 30 days.

About Vir Biotechnology
Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B and D viruses, influenza A and human immunodeficiency virus. Vir routinely posts information that may be important to investors on its website.


CONTACT: Contact: Carly Scaduto Senior Director, Media Relations  cscaduto@vir.bio +1-314-368-5189